Racial differences in 2L treatment choices could be related to socioeconomic factors and access to care, potential differences in tumor biology (e.g. less targetable mutations, such as the PIK3CA mutation, for subsequent endocrine treatments, or possible provider concerns related to drug toxicities or efficacy. This evidence concerns the gene PIK3CA and neoplasm.